Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Target Lowered at Piper Sandler

Posted by Francis Steltz on Nov 6th, 2026

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) had its target price cut by investment analysts at Piper Sandler from $43.00 to $28.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the specialty pharmaceutical company’s stock. Piper Sandler‘s price target points to a potential upside of 11.29% from the stock’s previous close.

A number of other research analysts also recently commented on the company. Barclays dropped their price target on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, August 19th. Leerink Partners started coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective on the stock. Oppenheimer started coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 target price for the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price target on shares of Collegium Pharmaceutical in a report on Friday. Finally, Truist Financial started coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set a “buy” rating and a $49.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $44.88.

Get Our Latest Stock Report on Collegium Pharmaceutical

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $25.16 on Friday. The stock’s fifty day moving average price is $23.04 and its two-hundred day moving average price is $32.91. Collegium Pharmaceutical has a one year low of $21.43 and a one year high of $50.79. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The firm has a market cap of $819.21 million, a PE ratio of 3.39, a price-to-earnings-growth ratio of 0.74 and a beta of 0.75.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.10. The firm had revenue of $216.34 million during the quarter, compared to analysts’ expectations of $216.03 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The company’s quarterly revenue was up 67.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.25 EPS. As a group, research analysts expect that Collegium Pharmaceutical will post 6.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently made changes to their positions in COLL. Ritholtz Wealth Management grew its position in shares of Collegium Pharmaceutical by 150.7% in the 3rd quarter. Ritholtz Wealth Management now owns 20,305 shares of the specialty pharmaceutical company’s stock valued at $443,000 after buying an additional 12,205 shares during the last quarter. Illinois Municipal Retirement Fund raised its position in shares of Collegium Pharmaceutical by 10.0% during the third quarter. Illinois Municipal Retirement Fund now owns 17,696 shares of the specialty pharmaceutical company’s stock worth $386,000 after acquiring an additional 1,607 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Collegium Pharmaceutical during the third quarter worth about $36,000. Profund Advisors LLC lifted its stake in shares of Collegium Pharmaceutical by 621.1% in the third quarter. Profund Advisors LLC now owns 65,710 shares of the specialty pharmaceutical company’s stock worth $1,434,000 after acquiring an additional 56,597 shares during the period. Finally, Vise Technologies Inc. lifted its stake in shares of Collegium Pharmaceutical by 154.3% in the third quarter. Vise Technologies Inc. now owns 14,844 shares of the specialty pharmaceutical company’s stock worth $324,000 after acquiring an additional 9,006 shares during the period.

Trending Headlines about Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

Positive Sentiment: Q3 adjusted earnings were $1.96 per share, above the cited analyst consensus of $1.86, and revenue of $216.3 million was slightly ahead of estimates. Revenue reached a quarterly record and grew 3% year over year. Collegium Q3 results and guidance
Positive Sentiment: Collegium reaffirmed 2026 revenue guidance of $825 million to $855 million, a range with a midpoint above the reported analyst consensus of $832.9 million. The outlook may have helped investor sentiment. Q3 sales and full-year revenue guidance
Positive Sentiment: Product trends were encouraging: JORNAY PM revenue increased 24% year over year to $51.9 million, while AZSTARYS generated $26.5 million in its first full quarter under Collegium ownership. The company also announced a $50 million accelerated share repurchase. Quarterly results release
Negative Sentiment: Needham lowered its price target to $44 from $46, although it maintained a Buy rating. Q3 earnings per share were also below the year-ago $2.25, despite beating the current-quarter consensus. Needham price target change

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.